nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.356	0.708	CbGbCtD
Imatinib—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.147	0.292	CbGbCtD
Imatinib—Prostate cancer—Riluzole—amyotrophic lateral sclerosis	0.01	0.0385	CcSEcCtD
Imatinib—Subdural haematoma—Riluzole—amyotrophic lateral sclerosis	0.00917	0.0352	CcSEcCtD
Imatinib—Osteonecrosis—Riluzole—amyotrophic lateral sclerosis	0.00516	0.0198	CcSEcCtD
Imatinib—Cheilitis—Riluzole—amyotrophic lateral sclerosis	0.00452	0.0173	CcSEcCtD
Imatinib—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.00445	0.017	CcSEcCtD
Imatinib—White blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.00386	0.0148	CcSEcCtD
Imatinib—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00376	0.0144	CcSEcCtD
Imatinib—Renal pain—Riluzole—amyotrophic lateral sclerosis	0.00366	0.014	CcSEcCtD
Imatinib—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00347	0.0133	CcSEcCtD
Imatinib—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00331	0.0127	CcSEcCtD
Imatinib—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00323	0.0124	CcSEcCtD
Imatinib—Generalised oedema—Riluzole—amyotrophic lateral sclerosis	0.00323	0.0124	CcSEcCtD
Imatinib—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0121	CcSEcCtD
Imatinib—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.00313	0.012	CcSEcCtD
Imatinib—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00306	0.0117	CcSEcCtD
Imatinib—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.00303	0.0116	CcSEcCtD
Imatinib—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00299	0.0115	CcSEcCtD
Imatinib—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00288	0.011	CcSEcCtD
Imatinib—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.00282	0.0108	CcSEcCtD
Imatinib—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.00279	0.0107	CcSEcCtD
Imatinib—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.00279	0.0107	CcSEcCtD
Imatinib—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00277	0.0106	CcSEcCtD
Imatinib—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00277	0.0106	CcSEcCtD
Imatinib—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00272	0.0104	CcSEcCtD
Imatinib—Ileus—Riluzole—amyotrophic lateral sclerosis	0.00272	0.0104	CcSEcCtD
Imatinib—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00272	0.0104	CcSEcCtD
Imatinib—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00255	0.00979	CcSEcCtD
Imatinib—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00251	0.00963	CcSEcCtD
Imatinib—NQO2—hindbrain—amyotrophic lateral sclerosis	0.00246	0.0241	CbGeAlD
Imatinib—CA1—nerve—amyotrophic lateral sclerosis	0.00239	0.0235	CbGeAlD
Imatinib—ABCA3—medulla oblongata—amyotrophic lateral sclerosis	0.00235	0.023	CbGeAlD
Imatinib—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00234	0.00896	CcSEcCtD
Imatinib—DDR1—medulla oblongata—amyotrophic lateral sclerosis	0.00217	0.0212	CbGeAlD
Imatinib—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00822	CcSEcCtD
Imatinib—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00816	CcSEcCtD
Imatinib—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00811	CcSEcCtD
Imatinib—ABCA3—spinal cord—amyotrophic lateral sclerosis	0.00209	0.0205	CbGeAlD
Imatinib—Gout—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0079	CcSEcCtD
Imatinib—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00779	CcSEcCtD
Imatinib—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00779	CcSEcCtD
Imatinib—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00774	CcSEcCtD
Imatinib—SLC47A1—hindbrain—amyotrophic lateral sclerosis	0.00197	0.0193	CbGeAlD
Imatinib—KIT—hindbrain—amyotrophic lateral sclerosis	0.00196	0.0192	CbGeAlD
Imatinib—DDR1—spinal cord—amyotrophic lateral sclerosis	0.00193	0.0189	CbGeAlD
Imatinib—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00737	CcSEcCtD
Imatinib—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00188	0.0072	CcSEcCtD
Imatinib—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00183	0.007	CcSEcCtD
Imatinib—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00692	CcSEcCtD
Imatinib—ABCA3—nervous system—amyotrophic lateral sclerosis	0.00176	0.0173	CbGeAlD
Imatinib—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00667	CcSEcCtD
Imatinib—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00667	CcSEcCtD
Imatinib—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00656	CcSEcCtD
Imatinib—ABL1—hindbrain—amyotrophic lateral sclerosis	0.00171	0.0167	CbGeAlD
Imatinib—ABCA3—central nervous system—amyotrophic lateral sclerosis	0.0017	0.0166	CbGeAlD
Imatinib—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00167	0.0064	CcSEcCtD
Imatinib—ABCA3—cerebellum—amyotrophic lateral sclerosis	0.00166	0.0163	CbGeAlD
Imatinib—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00627	CcSEcCtD
Imatinib—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00615	CcSEcCtD
Imatinib—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00598	CcSEcCtD
Imatinib—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00598	CcSEcCtD
Imatinib—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00595	CcSEcCtD
Imatinib—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00154	0.0059	CcSEcCtD
Imatinib—PDGFRA—embryo—amyotrophic lateral sclerosis	0.00153	0.015	CbGeAlD
Imatinib—DDR1—cerebellum—amyotrophic lateral sclerosis	0.00153	0.015	CbGeAlD
Imatinib—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00577	CcSEcCtD
Imatinib—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00149	0.0057	CcSEcCtD
Imatinib—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00567	CcSEcCtD
Imatinib—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00565	CcSEcCtD
Imatinib—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00555	CcSEcCtD
Imatinib—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00551	CcSEcCtD
Imatinib—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00548	CcSEcCtD
Imatinib—NQO2—brainstem—amyotrophic lateral sclerosis	0.00141	0.0138	CbGeAlD
Imatinib—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00537	CcSEcCtD
Imatinib—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00535	CcSEcCtD
Imatinib—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00531	CcSEcCtD
Imatinib—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00527	CcSEcCtD
Imatinib—HIPK4—brain—amyotrophic lateral sclerosis	0.00136	0.0134	CbGeAlD
Imatinib—CSF1R—embryo—amyotrophic lateral sclerosis	0.00135	0.0132	CbGeAlD
Imatinib—ABCA3—brain—amyotrophic lateral sclerosis	0.00135	0.0132	CbGeAlD
Imatinib—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00517	CcSEcCtD
Imatinib—PIP4K2C—medulla oblongata—amyotrophic lateral sclerosis	0.00134	0.0131	CbGeAlD
Imatinib—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00509	CcSEcCtD
Imatinib—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00498	CcSEcCtD
Imatinib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00487	CcSEcCtD
Imatinib—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00484	CcSEcCtD
Imatinib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00482	CcSEcCtD
Imatinib—DDR1—brain—amyotrophic lateral sclerosis	0.00124	0.0122	CbGeAlD
Imatinib—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00474	CcSEcCtD
Imatinib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00472	CcSEcCtD
Imatinib—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00472	CcSEcCtD
Imatinib—KIT—embryo—amyotrophic lateral sclerosis	0.00123	0.012	CbGeAlD
Imatinib—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00466	CcSEcCtD
Imatinib—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00463	CcSEcCtD
Imatinib—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00463	CcSEcCtD
Imatinib—PDGFRB—embryo—amyotrophic lateral sclerosis	0.0012	0.0117	CbGeAlD
Imatinib—PIP4K2C—spinal cord—amyotrophic lateral sclerosis	0.00119	0.0117	CbGeAlD
Imatinib—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00453	CcSEcCtD
Imatinib—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00451	CcSEcCtD
Imatinib—CA2—hindbrain—amyotrophic lateral sclerosis	0.00116	0.0114	CbGeAlD
Imatinib—CA14—medulla oblongata—amyotrophic lateral sclerosis	0.00116	0.0114	CbGeAlD
Imatinib—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00439	CcSEcCtD
Imatinib—SLC47A1—brainstem—amyotrophic lateral sclerosis	0.00113	0.0111	CbGeAlD
Imatinib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00432	CcSEcCtD
Imatinib—KIT—brainstem—amyotrophic lateral sclerosis	0.00112	0.011	CbGeAlD
Imatinib—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00427	CcSEcCtD
Imatinib—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00426	CcSEcCtD
Imatinib—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00422	CcSEcCtD
Imatinib—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00421	CcSEcCtD
Imatinib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00418	CcSEcCtD
Imatinib—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00415	CcSEcCtD
Imatinib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00412	CcSEcCtD
Imatinib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00412	CcSEcCtD
Imatinib—Depression—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00411	CcSEcCtD
Imatinib—ABL1—embryo—amyotrophic lateral sclerosis	0.00107	0.0105	CbGeAlD
Imatinib—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00407	CcSEcCtD
Imatinib—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00404	CcSEcCtD
Imatinib—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00404	CcSEcCtD
Imatinib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00402	CcSEcCtD
Imatinib—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00402	CcSEcCtD
Imatinib—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00401	CcSEcCtD
Imatinib—CA14—spinal cord—amyotrophic lateral sclerosis	0.00103	0.0101	CbGeAlD
Imatinib—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00395	CcSEcCtD
Imatinib—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00393	CcSEcCtD
Imatinib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00102	0.0039	CcSEcCtD
Imatinib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00389	CcSEcCtD
Imatinib—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00387	CcSEcCtD
Imatinib—PIP4K2C—nervous system—amyotrophic lateral sclerosis	0.001	0.00985	CbGeAlD
Imatinib—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.001	0.00385	CcSEcCtD
Imatinib—ABL2—cerebellum—amyotrophic lateral sclerosis	0.000999	0.0098	CbGeAlD
Imatinib—CA7—cerebellum—amyotrophic lateral sclerosis	0.000984	0.00965	CbGeAlD
Imatinib—NQO2—medulla oblongata—amyotrophic lateral sclerosis	0.000982	0.00963	CbGeAlD
Imatinib—ABL1—brainstem—amyotrophic lateral sclerosis	0.000977	0.00958	CbGeAlD
Imatinib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00097	0.00372	CcSEcCtD
Imatinib—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000968	0.00371	CcSEcCtD
Imatinib—PIP4K2C—central nervous system—amyotrophic lateral sclerosis	0.000967	0.00948	CbGeAlD
Imatinib—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000965	0.0037	CcSEcCtD
Imatinib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000965	0.0037	CcSEcCtD
Imatinib—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.000961	0.00368	CcSEcCtD
Imatinib—CA3—nervous system—amyotrophic lateral sclerosis	0.000959	0.0094	CbGeAlD
Imatinib—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000958	0.00367	CcSEcCtD
Imatinib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000953	0.00366	CcSEcCtD
Imatinib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000951	0.00365	CcSEcCtD
Imatinib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000949	0.00364	CcSEcCtD
Imatinib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000946	0.00363	CcSEcCtD
Imatinib—PIP4K2C—cerebellum—amyotrophic lateral sclerosis	0.000945	0.00927	CbGeAlD
Imatinib—CA3—central nervous system—amyotrophic lateral sclerosis	0.000923	0.00905	CbGeAlD
Imatinib—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000913	0.0035	CcSEcCtD
Imatinib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000902	0.00346	CcSEcCtD
Imatinib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000896	0.00344	CcSEcCtD
Imatinib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000876	0.00336	CcSEcCtD
Imatinib—NQO2—spinal cord—amyotrophic lateral sclerosis	0.000875	0.00858	CbGeAlD
Imatinib—PDGFRA—spinal cord—amyotrophic lateral sclerosis	0.000873	0.00856	CbGeAlD
Imatinib—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000872	0.00334	CcSEcCtD
Imatinib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00087	0.00334	CcSEcCtD
Imatinib—Chills—Riluzole—amyotrophic lateral sclerosis	0.000866	0.00332	CcSEcCtD
Imatinib—CA9—cerebellum—amyotrophic lateral sclerosis	0.000864	0.00847	CbGeAlD
Imatinib—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000862	0.00331	CcSEcCtD
Imatinib—CSF1R—medulla oblongata—amyotrophic lateral sclerosis	0.000862	0.00845	CbGeAlD
Imatinib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000853	0.00327	CcSEcCtD
Imatinib—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000846	0.00324	CcSEcCtD
Imatinib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00084	0.00322	CcSEcCtD
Imatinib—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000828	0.00318	CcSEcCtD
Imatinib—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000823	0.00316	CcSEcCtD
Imatinib—CA14—cerebellum—amyotrophic lateral sclerosis	0.000819	0.00804	CbGeAlD
Imatinib—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000813	0.00312	CcSEcCtD
Imatinib—ABL2—brain—amyotrophic lateral sclerosis	0.000811	0.00796	CbGeAlD
Imatinib—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000808	0.0031	CcSEcCtD
Imatinib—CA7—brain—amyotrophic lateral sclerosis	0.000799	0.00784	CbGeAlD
Imatinib—SLC47A1—medulla oblongata—amyotrophic lateral sclerosis	0.000787	0.00772	CbGeAlD
Imatinib—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000787	0.00302	CcSEcCtD
Imatinib—KIT—medulla oblongata—amyotrophic lateral sclerosis	0.000783	0.00768	CbGeAlD
Imatinib—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00078	0.00299	CcSEcCtD
Imatinib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000777	0.00298	CcSEcCtD
Imatinib—CSF1R—spinal cord—amyotrophic lateral sclerosis	0.000769	0.00754	CbGeAlD
Imatinib—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000768	0.00294	CcSEcCtD
Imatinib—PIP4K2C—brain—amyotrophic lateral sclerosis	0.000768	0.00753	CbGeAlD
Imatinib—PDGFRB—medulla oblongata—amyotrophic lateral sclerosis	0.000765	0.0075	CbGeAlD
Imatinib—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000758	0.00291	CcSEcCtD
Imatinib—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000755	0.0029	CcSEcCtD
Imatinib—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000754	0.00289	CcSEcCtD
Imatinib—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000752	0.00288	CcSEcCtD
Imatinib—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000743	0.00285	CcSEcCtD
Imatinib—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000739	0.00283	CcSEcCtD
Imatinib—NQO2—nervous system—amyotrophic lateral sclerosis	0.000738	0.00723	CbGeAlD
Imatinib—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000737	0.00723	CbGeAlD
Imatinib—PDGFRA—nervous system—amyotrophic lateral sclerosis	0.000736	0.00721	CbGeAlD
Imatinib—Cough—Riluzole—amyotrophic lateral sclerosis	0.000733	0.00281	CcSEcCtD
Imatinib—CA3—brain—amyotrophic lateral sclerosis	0.000733	0.00719	CbGeAlD
Imatinib—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000728	0.00279	CcSEcCtD
Imatinib—CA2—embryo—amyotrophic lateral sclerosis	0.000726	0.00712	CbGeAlD
Imatinib—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000726	0.00278	CcSEcCtD
Imatinib—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000715	0.00274	CcSEcCtD
Imatinib—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000715	0.00274	CcSEcCtD
Imatinib—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000715	0.00274	CcSEcCtD
Imatinib—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000713	0.00273	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000711	0.00272	CcSEcCtD
Imatinib—NQO2—central nervous system—amyotrophic lateral sclerosis	0.00071	0.00696	CbGeAlD
Imatinib—PDGFRA—central nervous system—amyotrophic lateral sclerosis	0.000708	0.00695	CbGeAlD
Imatinib—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000707	0.00271	CcSEcCtD
Imatinib—SLC47A1—spinal cord—amyotrophic lateral sclerosis	0.000702	0.00688	CbGeAlD
Imatinib—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00268	CcSEcCtD
Imatinib—KIT—spinal cord—amyotrophic lateral sclerosis	0.000698	0.00685	CbGeAlD
Imatinib—NQO2—cerebellum—amyotrophic lateral sclerosis	0.000694	0.00681	CbGeAlD
Imatinib—PDGFRA—cerebellum—amyotrophic lateral sclerosis	0.000692	0.00679	CbGeAlD
Imatinib—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000692	0.00265	CcSEcCtD
Imatinib—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000686	0.00263	CcSEcCtD
Imatinib—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000686	0.00263	CcSEcCtD
Imatinib—PDGFRB—spinal cord—amyotrophic lateral sclerosis	0.000682	0.00669	CbGeAlD
Imatinib—ABL1—medulla oblongata—amyotrophic lateral sclerosis	0.000682	0.00668	CbGeAlD
Imatinib—Infection—Riluzole—amyotrophic lateral sclerosis	0.000681	0.00261	CcSEcCtD
Imatinib—CA12—nervous system—amyotrophic lateral sclerosis	0.000679	0.00666	CbGeAlD
Imatinib—Shock—Riluzole—amyotrophic lateral sclerosis	0.000675	0.00259	CcSEcCtD
Imatinib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000673	0.00258	CcSEcCtD
Imatinib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000672	0.00258	CcSEcCtD
Imatinib—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000669	0.00257	CcSEcCtD
Imatinib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000666	0.00255	CcSEcCtD
Imatinib—CA14—brain—amyotrophic lateral sclerosis	0.000666	0.00653	CbGeAlD
Imatinib—CA2—brainstem—amyotrophic lateral sclerosis	0.000666	0.00653	CbGeAlD
Imatinib—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000663	0.00254	CcSEcCtD
Imatinib—CA12—central nervous system—amyotrophic lateral sclerosis	0.000654	0.00641	CbGeAlD
Imatinib—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000654	0.00251	CcSEcCtD
Imatinib—CSF1R—nervous system—amyotrophic lateral sclerosis	0.000648	0.00635	CbGeAlD
Imatinib—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000641	0.00246	CcSEcCtD
Imatinib—ORM1—spinal cord—amyotrophic lateral sclerosis	0.00064	0.00627	CbGeAlD
Imatinib—CA1—spinal cord—amyotrophic lateral sclerosis	0.000638	0.00626	CbGeAlD
Imatinib—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000625	0.0024	CcSEcCtD
Imatinib—CSF1R—central nervous system—amyotrophic lateral sclerosis	0.000624	0.00612	CbGeAlD
Imatinib—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00062	0.00238	CcSEcCtD
Imatinib—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000616	0.00236	CcSEcCtD
Imatinib—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000611	0.00234	CcSEcCtD
Imatinib—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00061	0.00234	CcSEcCtD
Imatinib—CSF1R—cerebellum—amyotrophic lateral sclerosis	0.00061	0.00598	CbGeAlD
Imatinib—ABL1—spinal cord—amyotrophic lateral sclerosis	0.000608	0.00596	CbGeAlD
Imatinib—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000604	0.00232	CcSEcCtD
Imatinib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000596	0.00229	CcSEcCtD
Imatinib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000592	0.00227	CcSEcCtD
Imatinib—SLC47A1—nervous system—amyotrophic lateral sclerosis	0.000592	0.0058	CbGeAlD
Imatinib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000591	0.00227	CcSEcCtD
Imatinib—KIT—nervous system—amyotrophic lateral sclerosis	0.000588	0.00577	CbGeAlD
Imatinib—Pain—Riluzole—amyotrophic lateral sclerosis	0.000587	0.00225	CcSEcCtD
Imatinib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000587	0.00225	CcSEcCtD
Imatinib—PDGFRB—nervous system—amyotrophic lateral sclerosis	0.000575	0.00563	CbGeAlD
Imatinib—SLC47A1—central nervous system—amyotrophic lateral sclerosis	0.00057	0.00559	CbGeAlD
Imatinib—KIT—central nervous system—amyotrophic lateral sclerosis	0.000566	0.00555	CbGeAlD
Imatinib—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000565	0.00217	CcSEcCtD
Imatinib—NQO2—brain—amyotrophic lateral sclerosis	0.000564	0.00553	CbGeAlD
Imatinib—PDGFRA—brain—amyotrophic lateral sclerosis	0.000562	0.00551	CbGeAlD
Imatinib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000561	0.00215	CcSEcCtD
Imatinib—SLC47A1—cerebellum—amyotrophic lateral sclerosis	0.000557	0.00546	CbGeAlD
Imatinib—KIT—cerebellum—amyotrophic lateral sclerosis	0.000554	0.00543	CbGeAlD
Imatinib—PDGFRB—central nervous system—amyotrophic lateral sclerosis	0.000553	0.00542	CbGeAlD
Imatinib—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000545	0.00209	CcSEcCtD
Imatinib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000542	0.00208	CcSEcCtD
Imatinib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000542	0.00208	CcSEcCtD
Imatinib—PDGFRB—cerebellum—amyotrophic lateral sclerosis	0.000541	0.0053	CbGeAlD
Imatinib—ORM1—nervous system—amyotrophic lateral sclerosis	0.000539	0.00528	CbGeAlD
Imatinib—CA1—nervous system—amyotrophic lateral sclerosis	0.000538	0.00528	CbGeAlD
Imatinib—CA12—brain—amyotrophic lateral sclerosis	0.000519	0.00509	CbGeAlD
Imatinib—ORM1—central nervous system—amyotrophic lateral sclerosis	0.000519	0.00509	CbGeAlD
Imatinib—CA1—central nervous system—amyotrophic lateral sclerosis	0.000518	0.00508	CbGeAlD
Imatinib—ABL1—nervous system—amyotrophic lateral sclerosis	0.000512	0.00502	CbGeAlD
Imatinib—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000505	0.00194	CcSEcCtD
Imatinib—CSF1R—brain—amyotrophic lateral sclerosis	0.000495	0.00486	CbGeAlD
Imatinib—SLC22A1—nervous system—amyotrophic lateral sclerosis	0.000494	0.00484	CbGeAlD
Imatinib—ABL1—central nervous system—amyotrophic lateral sclerosis	0.000493	0.00483	CbGeAlD
Imatinib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000492	0.00189	CcSEcCtD
Imatinib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000485	0.00186	CcSEcCtD
Imatinib—ABL1—cerebellum—amyotrophic lateral sclerosis	0.000482	0.00473	CbGeAlD
Imatinib—SLC22A1—central nervous system—amyotrophic lateral sclerosis	0.000475	0.00466	CbGeAlD
Imatinib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000469	0.0018	CcSEcCtD
Imatinib—CA2—medulla oblongata—amyotrophic lateral sclerosis	0.000464	0.00455	CbGeAlD
Imatinib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000454	0.00174	CcSEcCtD
Imatinib—SLC47A1—brain—amyotrophic lateral sclerosis	0.000452	0.00443	CbGeAlD
Imatinib—KIT—brain—amyotrophic lateral sclerosis	0.00045	0.00441	CbGeAlD
Imatinib—PDGFRB—brain—amyotrophic lateral sclerosis	0.000439	0.00431	CbGeAlD
Imatinib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000436	0.00167	CcSEcCtD
Imatinib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000432	0.00166	CcSEcCtD
Imatinib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000432	0.00166	CcSEcCtD
Imatinib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.00043	0.00421	CbGeAlD
Imatinib—Headache—Riluzole—amyotrophic lateral sclerosis	0.00043	0.00165	CcSEcCtD
Imatinib—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000423	0.00414	CbGeAlD
Imatinib—CA2—spinal cord—amyotrophic lateral sclerosis	0.000414	0.00406	CbGeAlD
Imatinib—CA1—brain—amyotrophic lateral sclerosis	0.000411	0.00403	CbGeAlD
Imatinib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000407	0.00156	CcSEcCtD
Imatinib—ABL1—brain—amyotrophic lateral sclerosis	0.000391	0.00384	CbGeAlD
Imatinib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000383	0.00376	CbGeAlD
Imatinib—SLC22A1—brain—amyotrophic lateral sclerosis	0.000377	0.0037	CbGeAlD
Imatinib—ALB—brain—amyotrophic lateral sclerosis	0.000361	0.00354	CbGeAlD
Imatinib—CA2—nervous system—amyotrophic lateral sclerosis	0.000349	0.00342	CbGeAlD
Imatinib—CA2—central nervous system—amyotrophic lateral sclerosis	0.000336	0.00329	CbGeAlD
Imatinib—ABCB1—embryo—amyotrophic lateral sclerosis	0.000332	0.00325	CbGeAlD
Imatinib—CA2—cerebellum—amyotrophic lateral sclerosis	0.000328	0.00322	CbGeAlD
Imatinib—PTGS1—spinal cord—amyotrophic lateral sclerosis	0.00032	0.00313	CbGeAlD
Imatinib—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000304	0.00298	CbGeAlD
Imatinib—PTGS1—nervous system—amyotrophic lateral sclerosis	0.000269	0.00264	CbGeAlD
Imatinib—CA2—brain—amyotrophic lateral sclerosis	0.000267	0.00261	CbGeAlD
Imatinib—PTGS1—central nervous system—amyotrophic lateral sclerosis	0.000259	0.00254	CbGeAlD
Imatinib—ABCG2—brain—amyotrophic lateral sclerosis	0.000247	0.00242	CbGeAlD
Imatinib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000225	0.00221	CbGeAlD
Imatinib—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000221	0.00217	CbGeAlD
Imatinib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000217	0.00212	CbGeAlD
Imatinib—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000213	0.00209	CbGeAlD
Imatinib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000212	0.00208	CbGeAlD
Imatinib—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000208	0.00204	CbGeAlD
Imatinib—PTGS1—brain—amyotrophic lateral sclerosis	0.000206	0.00202	CbGeAlD
Imatinib—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000189	0.00185	CbGeAlD
Imatinib—CYP2D6—brain—amyotrophic lateral sclerosis	0.000169	0.00166	CbGeAlD
Imatinib—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000159	0.00156	CbGeAlD
Imatinib—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000153	0.0015	CbGeAlD
Imatinib—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.00015	0.00147	CbGeAlD
Imatinib—ABCB1—brain—amyotrophic lateral sclerosis	0.000122	0.00119	CbGeAlD
Imatinib—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.74e-05	0.000205	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	2.73e-05	0.000204	CbGpPWpGaD
Imatinib—LCK—Disease—CST3—amyotrophic lateral sclerosis	2.73e-05	0.000204	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.73e-05	0.000204	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.73e-05	0.000204	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	2.73e-05	0.000204	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—IGF1—amyotrophic lateral sclerosis	2.73e-05	0.000204	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.72e-05	0.000203	CbGpPWpGaD
Imatinib—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.71e-05	0.000203	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.7e-05	0.000202	CbGpPWpGaD
Imatinib—KIT—Immune System—ERBB4—amyotrophic lateral sclerosis	2.69e-05	0.000201	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CASP9—amyotrophic lateral sclerosis	2.68e-05	0.0002	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.67e-05	0.000199	CbGpPWpGaD
Imatinib—CA14—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.66e-05	0.000199	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—C3—amyotrophic lateral sclerosis	2.63e-05	0.000196	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.63e-05	0.000196	CbGpPWpGaD
Imatinib—ABL1—Immune System—CASP9—amyotrophic lateral sclerosis	2.61e-05	0.000195	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	2.6e-05	0.000195	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—CHAT—amyotrophic lateral sclerosis	2.6e-05	0.000195	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.6e-05	0.000194	CbGpPWpGaD
Imatinib—CA6—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.6e-05	0.000194	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.58e-05	0.000193	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	2.58e-05	0.000193	CbGpPWpGaD
Imatinib—CA9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.57e-05	0.000192	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	2.56e-05	0.000192	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	2.55e-05	0.000191	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—ERBB4—amyotrophic lateral sclerosis	2.55e-05	0.00019	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.55e-05	0.00019	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.54e-05	0.00019	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	2.53e-05	0.000189	CbGpPWpGaD
Imatinib—KIT—Immune System—CD40LG—amyotrophic lateral sclerosis	2.53e-05	0.000189	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.52e-05	0.000189	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—C3—amyotrophic lateral sclerosis	2.52e-05	0.000189	CbGpPWpGaD
Imatinib—CA2—Metabolism—APOE—amyotrophic lateral sclerosis	2.51e-05	0.000187	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.5e-05	0.000187	CbGpPWpGaD
Imatinib—KIT—Disease—ERBB4—amyotrophic lateral sclerosis	2.49e-05	0.000186	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	2.48e-05	0.000186	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CASP9—amyotrophic lateral sclerosis	2.48e-05	0.000185	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	2.47e-05	0.000185	CbGpPWpGaD
Imatinib—CA7—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.42e-05	0.000181	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.42e-05	0.000181	CbGpPWpGaD
Imatinib—LCK—Immune System—SQSTM1—amyotrophic lateral sclerosis	2.41e-05	0.00018	CbGpPWpGaD
Imatinib—CA1—Metabolism—APOE—amyotrophic lateral sclerosis	2.4e-05	0.00018	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD40LG—amyotrophic lateral sclerosis	2.4e-05	0.000179	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.38e-05	0.000178	CbGpPWpGaD
Imatinib—PDGFRA—Disease—ERBB4—amyotrophic lateral sclerosis	2.35e-05	0.000176	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	2.33e-05	0.000174	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.32e-05	0.000174	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	2.31e-05	0.000173	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.3e-05	0.000172	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—ERBB4—amyotrophic lateral sclerosis	2.3e-05	0.000172	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.29e-05	0.000171	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	2.29e-05	0.000171	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.28e-05	0.00017	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.27e-05	0.000169	CbGpPWpGaD
Imatinib—LCK—Immune System—ATF1—amyotrophic lateral sclerosis	2.26e-05	0.000169	CbGpPWpGaD
Imatinib—CA12—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.25e-05	0.000168	CbGpPWpGaD
Imatinib—LCK—Hemostasis—IGF1—amyotrophic lateral sclerosis	2.25e-05	0.000168	CbGpPWpGaD
Imatinib—ABL1—Immune System—ERBB4—amyotrophic lateral sclerosis	2.24e-05	0.000167	CbGpPWpGaD
Imatinib—KIT—Immune System—C3—amyotrophic lateral sclerosis	2.24e-05	0.000167	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.23e-05	0.000167	CbGpPWpGaD
Imatinib—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	2.2e-05	0.000165	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.18e-05	0.000163	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD40LG—amyotrophic lateral sclerosis	2.16e-05	0.000161	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.15e-05	0.000161	CbGpPWpGaD
Imatinib—LCK—Immune System—CASP9—amyotrophic lateral sclerosis	2.15e-05	0.000161	CbGpPWpGaD
Imatinib—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	2.14e-05	0.00016	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.13e-05	0.00016	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	2.13e-05	0.000159	CbGpPWpGaD
Imatinib—PDGFRB—Disease—ERBB4—amyotrophic lateral sclerosis	2.12e-05	0.000158	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—C3—amyotrophic lateral sclerosis	2.12e-05	0.000158	CbGpPWpGaD
Imatinib—CA9—Metabolism—APOE—amyotrophic lateral sclerosis	2.11e-05	0.000158	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.11e-05	0.000157	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.11e-05	0.000157	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD40LG—amyotrophic lateral sclerosis	2.1e-05	0.000157	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.03e-05	0.000152	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.02e-05	0.000151	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.02e-05	0.000151	CbGpPWpGaD
Imatinib—LCK—Disease—CASP9—amyotrophic lateral sclerosis	1.99e-05	0.000149	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	1.97e-05	0.000148	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	1.97e-05	0.000148	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.97e-05	0.000148	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	1.97e-05	0.000148	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.97e-05	0.000148	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.94e-05	0.000145	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.93e-05	0.000144	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.92e-05	0.000144	CbGpPWpGaD
Imatinib—KIT—Disease—APOE—amyotrophic lateral sclerosis	1.92e-05	0.000144	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	1.92e-05	0.000143	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—C3—amyotrophic lateral sclerosis	1.91e-05	0.000143	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	1.88e-05	0.000141	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.87e-05	0.00014	CbGpPWpGaD
Imatinib—ABL1—Immune System—C3—amyotrophic lateral sclerosis	1.86e-05	0.000139	CbGpPWpGaD
Imatinib—LCK—Immune System—ERBB4—amyotrophic lateral sclerosis	1.84e-05	0.000138	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.84e-05	0.000137	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.82e-05	0.000136	CbGpPWpGaD
Imatinib—PDGFRA—Disease—APOE—amyotrophic lateral sclerosis	1.82e-05	0.000136	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.82e-05	0.000136	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.8e-05	0.000134	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.79e-05	0.000134	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.78e-05	0.000133	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	1.77e-05	0.000132	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.77e-05	0.000132	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	1.75e-05	0.000131	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.74e-05	0.00013	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.73e-05	0.00013	CbGpPWpGaD
Imatinib—LCK—Immune System—CD40LG—amyotrophic lateral sclerosis	1.73e-05	0.000129	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.73e-05	0.000129	CbGpPWpGaD
Imatinib—CA2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.72e-05	0.000128	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	1.7e-05	0.000127	CbGpPWpGaD
Imatinib—LCK—Disease—ERBB4—amyotrophic lateral sclerosis	1.7e-05	0.000127	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.68e-05	0.000126	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.67e-05	0.000125	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.65e-05	0.000123	CbGpPWpGaD
Imatinib—CA1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.65e-05	0.000123	CbGpPWpGaD
Imatinib—PDGFRB—Disease—APOE—amyotrophic lateral sclerosis	1.64e-05	0.000123	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.64e-05	0.000122	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.63e-05	0.000122	CbGpPWpGaD
Imatinib—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	1.62e-05	0.000121	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	1.62e-05	0.000121	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.61e-05	0.000121	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.58e-05	0.000118	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.56e-05	0.000116	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.55e-05	0.000116	CbGpPWpGaD
Imatinib—LCK—Immune System—C3—amyotrophic lateral sclerosis	1.53e-05	0.000114	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.52e-05	0.000114	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.52e-05	0.000113	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.5e-05	0.000112	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.48e-05	0.000111	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.48e-05	0.000111	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.47e-05	0.00011	CbGpPWpGaD
Imatinib—LCK—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.47e-05	0.00011	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.46e-05	0.000109	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	1.46e-05	0.000109	CbGpPWpGaD
Imatinib—CA9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.45e-05	0.000108	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.45e-05	0.000108	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.42e-05	0.000106	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.41e-05	0.000106	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.4e-05	0.000105	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.4e-05	0.000104	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.4e-05	0.000104	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.39e-05	0.000104	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.38e-05	0.000103	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.37e-05	0.000102	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.36e-05	0.000101	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.35e-05	0.000101	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—amyotrophic lateral sclerosis	1.35e-05	0.000101	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.34e-05	0.0001	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.34e-05	0.0001	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.33e-05	9.92e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.33e-05	9.92e-05	CbGpPWpGaD
Imatinib—KIT—Disease—PTGS2—amyotrophic lateral sclerosis	1.32e-05	9.85e-05	CbGpPWpGaD
Imatinib—LCK—Disease—APOE—amyotrophic lateral sclerosis	1.32e-05	9.83e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.3e-05	9.73e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.3e-05	9.7e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.29e-05	9.61e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.28e-05	9.6e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.27e-05	9.52e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.27e-05	9.46e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.26e-05	9.4e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PTGS2—amyotrophic lateral sclerosis	1.25e-05	9.32e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.25e-05	9.32e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.23e-05	9.22e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.21e-05	9.05e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.2e-05	8.94e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.19e-05	8.9e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.17e-05	8.73e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.15e-05	8.63e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.15e-05	8.58e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.13e-05	8.47e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PTGS2—amyotrophic lateral sclerosis	1.12e-05	8.4e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.12e-05	8.37e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.11e-05	8.31e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—amyotrophic lateral sclerosis	1.11e-05	8.28e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.1e-05	8.25e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	1.07e-05	7.98e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.07e-05	7.96e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	1.06e-05	7.91e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—APOE—amyotrophic lateral sclerosis	1.06e-05	7.9e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.05e-05	7.87e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.03e-05	7.73e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	1.03e-05	7.66e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.01e-05	7.57e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.01e-05	7.56e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.92e-06	7.41e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.9e-06	7.4e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—APOE—amyotrophic lateral sclerosis	9.85e-06	7.36e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.49e-06	7.09e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.3e-06	6.95e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.21e-06	6.89e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.1e-06	6.8e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTGS2—amyotrophic lateral sclerosis	9.02e-06	6.74e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	8.77e-06	6.55e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	8.75e-06	6.54e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.71e-06	6.51e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.56e-06	6.4e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.29e-06	6.2e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.11e-06	6.06e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.09e-06	6.05e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.01e-06	5.98e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.82e-06	5.84e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.66e-06	5.72e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	7.65e-06	5.72e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.63e-06	5.7e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.61e-06	5.69e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.49e-06	5.6e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.31e-06	5.47e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.3e-06	5.46e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.27e-06	5.43e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.25e-06	5.42e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.24e-06	5.41e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.19e-06	5.38e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.19e-06	5.37e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.13e-06	5.33e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.09e-06	5.3e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.03e-06	5.25e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.01e-06	5.24e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.9e-06	5.16e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.88e-06	5.14e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.75e-06	5.04e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	6.63e-06	4.95e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.61e-06	4.94e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	6.59e-06	4.92e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.55e-06	4.9e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.2e-06	4.63e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.09e-06	4.55e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	5.91e-06	4.42e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.86e-06	4.38e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	5.77e-06	4.31e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.6e-06	4.18e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.54e-06	4.14e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.49e-06	4.1e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	5.44e-06	4.06e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	5.39e-06	4.03e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.24e-06	3.92e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.2e-06	3.88e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.97e-06	3.72e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.7e-06	3.51e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.68e-06	3.5e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	4.61e-06	3.44e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.51e-06	3.37e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.32e-06	3.23e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.05e-06	3.03e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.95e-06	2.96e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.76e-06	2.81e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.73e-06	2.78e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.69e-06	2.76e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	3.56e-06	2.66e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.16e-06	2.36e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.44e-06	1.82e-05	CbGpPWpGaD
